Modular Medical, Inc. (MODD) Stock Price & Analysis
Modular Medical, Inc. (MODD) fell 17.43% to USD 2.51 as of July 26, 2026 at 11:07 UTC, according to Nexqual real-time market data.
MODD last closed at USD 3.04; the session ranged USD 2.44–3 on volume of 456,973 shares. Market capitalization is $13.59M, with a 52-week range of USD 2.44–30 (NCM). Source: Nexqual, July 26, 2026 at 11:07 UTC.
Key Statistics (as of July 26, 2026 at 11:07 UTC)
| Price | USD 2.51 |
|---|---|
| Change | ▼ 17.43% (down) |
| Previous Close | USD 3.04 |
| Open | USD 2.95 |
| Day Range | USD 2.44 – 3 |
| 52-Week Range | USD 2.44 – 30 |
| Volume | 456,973 shares |
| Market Cap | $13.59M |
| Exchange | NCM |
Technical Analysis (MODD)
Nexqual's technical model rates MODD "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 11:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.49 (neutral) |
| vs SMA50 | Below (USD 4.23) |
| MACD | -0.48 (negative) |
Analyst Ratings (MODD)
Wall Street analysts rate MODD "None", per Nexqual as of July 26, 2026 at 11:07 UTC.
| Consensus Rating | None |
|---|
Earnings (MODD)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD -3.9 vs est -3.6 ▼ miss |
| 2024-09-30 | USD -4.2 vs est -3.3 ▼ miss |
| 2024-06-30 | USD -3.6 vs est -5.55 ▲ beat |
| 2024-03-31 | USD -4.2 vs est -6 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:07 UTC.
Financials & Fundamentals (MODD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -188.05% |
| Debt / Equity | 3.03 |
| Current Ratio | 4.03 |
| Total Cash | $6.94M |
| Total Debt | $393,000 |
| Free Cash Flow | $-17.24M |
Source: Nexqual, July 26, 2026 at 11:07 UTC.
Financial Health Score (MODD)
Nexqual rates Modular Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 11:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$24M |
| Efficiency | Critical — ROE -188%, ROA -102.6% |
Ownership (MODD)
| Insider Ownership | +2.55% |
|---|---|
| Institutional Ownership | +31.21% |
| Shares Outstanding | 5.41M |
| Float | 4.63M |
| Short % of Float | +4.05% |
Source: Nexqual, July 26, 2026 at 11:07 UTC.
Leadership (MODD)
Modular Medical, Inc. is led by James E. Besser (age 49), Chief Executive Officer, per Nexqual as of July 26, 2026 at 11:07 UTC.
| Chief Executive Officer | James E. Besser (age 49) |
|---|---|
| Founder, Chairman, President, CFO & Treasurer | Paul M. DiPerna (age 66) |
| Chief Operating Officer | Kevin Schmid (age 66) |
Major Backers & Investors (MODD)
Notable institutional backers of Modular Medical, Inc. include AWM Investment Company, Inc., Solas Capital Management, LLC, Bleichroeder LP, according to Nexqual as of July 26, 2026 at 11:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AWM Investment Company, Inc. | 6.77% |
| Solas Capital Management, LLC | 5.32% |
| Bleichroeder LP | 3.45% |
| 683 Capital Management LLC | 2.31% |
| Bard Associates Inc. | 1.84% |
| Heights Capital Management, Inc | 0.92% |
| Sio Capital Management, LLC | 0.48% |
| Fidelity | 0.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.06% |
| Geode Capital | 0.51% |
Source: Nexqual, July 26, 2026 at 11:07 UTC.
From Modular Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-06-29)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe this represents a total addressable market of approximately $3 billion for us, assuming prescription cartridge revenue of approximately $4,100 per patient, per year.   5       We are dedicated to helping all people with diabetes gain access to high quality care.
- The patents and patent applications cover various aspects of our technology, including our proprietary fluid movement technology and associated features of our insulin delivery methodology.
- Class I devices are those for which reasonable assurance of safety and effectiveness can be maintained through adherence to general controls which include compliance with the applicable portions of the FDA's Quality System Regulation (the "QSR"), as well as regulations requiring facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials.
- We believe that, owing to our new proprietary technology, our Pivot pump is the simplest and least expensive product on the market and the easiest for providers to prescribe.   Our current pump has been built to test what we believe to be our novel approach to insulin pumps.
Partnerships
- Our pump products have been designed from the beginning for mass manufacturing, and we have partnered with Phillips Medisize to establish processes and "lights out" or near lights out production assembly lines whereby a minimal number of workers will be required in the production facility.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
| SVRE | SaverOne 2014 Ltd. | USD 3.56 | ▲ 5.33% |
| AIMD | Ainos, Inc. | USD 1.4 | ▼ 9.09% |
| BJDX | Bluejay Diagnostics, Inc. | USD 1.03 | ▼ 10.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:07 UTC. This page is informational and not investment advice.